Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy?

Journal of Surgical Oncology

Volumn 105, Issue 1, 2012, Pages 111-112

  Di Benedetto, Fabrizio ^a   Berretta, Massimiliano ^b   De Ruvo, Nicola ^a   Tarantino, Giuseppe ^a   D'Amico, Giuseppe ^a   Ballarin, Roberto ^a   Iemmolo, Rosa Maria ^a   Gerunda, Giorgio E ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; RIBAVIRIN; SORAFENIB;

ADVANCED CANCER; ANGIOGENESIS; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; DISEASE SEVERITY; HEPATITIS C; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER NODULE; LIVER TRANSPLANTATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; NEOADJUVANT THERAPY; PYRIDINES; SIROLIMUS; TREATMENT OUTCOME;

EID: 83555174312     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22039     Document Type: Letter

References (8)

1. El-Serag HB, Rudolph KL,: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576. (Pubitemid 46890874)
2. Roberts LR, Gores GJ,: Hepatocellular carcinoma: Molecular pathways and new therapeutic targets. Semin Liver Dis 2005; 25: 212-225. (Pubitemid 40781073)
3. Wilhelm SM, Carter C, Tang L, et al.: BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109. (Pubitemid 39331023)
4. Llovet J, Ricci S, Mazzaferro V, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
5. Guba M, von Breitenbuch P, Steinbauer M, et al.: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135. (Pubitemid 34155123)
6. Folkman J, Merler E, Abernathy C, et al.: Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275-288. (Semin Oncol 2002, 29(6 Suppl 16):15-18).
7. Folkman J,., Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-18.
8. Schumacher G, Oidtmann M, Rosewicz S, et al.: Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc 2002; 34: 1392-1393.